Drug Profile
DVC1 0401
Alternative Names: DVC1-0401Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator ID Pharma; Kyushu University
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinitis pigmentosa
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Retinitis-pigmentosa in Japan (Intraocular, Injection)
- 16 Mar 2021 DVC1 0401 is still in phase I trials for Retinitis-pigmentosa in Japan (ID Pharma pipeline, March 2021)
- 28 Feb 2021 No recent reports of development identified for phase-I development in Retinitis-pigmentosa in Japan (Intraocular, Injection)